Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bone marrow transplantation for refractory anemia]

Y Takemoto1, A Kanamaru

  • 1Department of Internal Medicine, Hyogo College of Medicine.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Herpesvirus Infection in Patients Following Bone Marrow Transplantation: Influence of Viral Reactivation on Prognosis.

Hematology (Amsterdam, Netherlands)·2016
Same author

Exogenous PML/RARα Fusion Gene Responds to All-trans Retinoic Acid Results in Differentiation of the Human B Cell Line.

Hematology (Amsterdam, Netherlands)·2016
Same author

Similarity Between Multiple Sclerosis and Idiopathic Central Nervous System Dysfunction After Bone Marrow Transplantation.

Hematology (Amsterdam, Netherlands)·2016
Same author

Cytokines and Cytomegalovirus Disease Following Allogeneic Bone Marrow Transplantation.

Hematology (Amsterdam, Netherlands)·2016
Same author

Acute Colonic Graft-versus-host Disease and Ulcerative Colitis with Respect to Cytokines.

Hematology (Amsterdam, Netherlands)·2016
Same author

A Case of Minimally Differentiated Acute Leukemia (AML-M0) Complicated by Ventricle Thrombosis During Remission-induction.

Hematology (Amsterdam, Netherlands)·2016

Allogeneic bone marrow transplantation (BMT) is a viable treatment for severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS). BMT is recommended for MDS patients with abnormal karyotypes or life-threatening complications, provided suitable donors are available.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Immunology

Context:

  • Allogeneic bone marrow transplantation (BMT) is a critical treatment for severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS).
  • Graft rejection and secondary malignancies, particularly with irradiation-based conditioning, pose significant challenges.
  • Determining optimal BMT indications for MDS subtypes, especially refractory anemia (RA), is essential for patient outcomes.

Purpose:

  • To evaluate the efficacy and indications of allogeneic bone marrow transplantation (BMT) for patients with severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS).
  • To identify patient characteristics and disease subtypes that benefit most from BMT.
  • To assess the survival rates and complications associated with BMT in this patient cohort.

Summary:

Related Experiment Videos

  • A study at Hyogo College of Medicine treated 19 SAA/MDS patients with BMT between 1980-1991.
  • BMT indications were considered for MDS with abnormal karyotypes or life-threatening complications.
  • Survival rates were 5/9 for MDS-RA and 4/10 for MDS RAEB-T/overt leukemia, suggesting BMT is beneficial for selected MDS patients.

Impact:

  • BMT is a recommended treatment for specific MDS patient groups, contingent on donor availability.
  • Further research is needed to determine the optimal pre-transplant strategy (chemotherapy vs. direct conditioning) for MDS with RAEB or overt leukemia.
  • This study informs clinical decision-making regarding BMT for hematologic malignancies.